{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:24:04Z","timestamp":1785860644957,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.nmd.2021.07.009","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T05:28:24Z","timestamp":1627450104000},"page":"931-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Congenital muscular dystrophies: What is new?"],"prefix":"10.1016","volume":"31","author":[{"given":"Alberto A.","family":"Zambon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.07.009_bib0001","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.spen.2011.10.010","article-title":"Congenital muscular dystrophies: a brief review","volume":"18","author":"Bertini","year":"2011","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0002","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/WNL.0000000000001303","article-title":"Prevalence of congenital muscular dystrophy in Italy: a population study","volume":"84","author":"Graziano","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.009_bib0003","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/cjn.2015.311","article-title":"A Systematic review and meta-analyze on the epidemiology of the muscular dystrophies","volume":"43","author":"Mah","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.07.009_bib0004","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/brain\/awp236","article-title":"Prevalence of genetic muscle disease in Northern England: in-depth analyze of a muscle clinic population","volume":"132","author":"Norwood","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2021.07.009_bib0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/01.wnl.0000284605.27654.5a","article-title":"Diagnosis and etiology of congenital muscular dystrophy","volume":"71","author":"Peat","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.009_bib0006","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.nmd.2017.06.008","article-title":"Congenital muscular dystrophies in the UK population: clinical and molecular spectrum of a large cohort diagnosed over a 12-year period","volume":"27","author":"Sframeli","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.009_bib0007","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.nmd.2012.01.010","article-title":"Relative frequency of congenital muscular dystrophy subtypes: analyze of the UK diagnostic service 2001-2008","volume":"22","author":"Clement","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.009_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ana.23548","article-title":"The ever-expanding spectrum of congenital muscular dystrophies","volume":"72","author":"Mercuri","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0009","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.nmd.2013.12.011","article-title":"Diagnostic approach to the congenital muscular dystrophies","volume":"24","author":"B\u00f6nnemann","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.009_bib0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/jnnp-2017-316956","article-title":"Mobility shift of beta-dystroglycan as a marker of GMPPB gene-related muscular dystrophy","volume":"89","author":"Sarkozy","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.07.009_bib0011","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ana.24687","article-title":"Diagnosis and etiology of congenital muscular dystrophy: we are halfway there","volume":"80","author":"O'Grady","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0012","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.0000000000001416","volume":"84","author":"Kang","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.009_bib0013","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.gde.2011.02.001","article-title":"Dystroglycanopathies: coming into focus","volume":"21","author":"Godfrey","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.nmd.2021.07.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.035931","article-title":"The roles of dystroglycan in the nervous system: insights from animal models of muscular dystrophy","volume":"11","author":"Nickolls","year":"2018","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.nmd.2021.07.009_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.matbio.2017.11.009","article-title":"Laminin-deficient muscular dystrophy: molecular pathogenesis and structural repair strategies","volume":"71-72","author":"Yurchenco","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fnmol.2020.00123","article-title":"LAMA2-related dystrophies: clinical phenotypes, disease biomarkers, and clinical trial readiness","volume":"13","author":"Sarkozy","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.nmd.2021.07.009_bib0017","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.nmd.2004.06.009","article-title":"The congenital muscular dystrophies in 2004: a century of exciting progress","volume":"14","author":"Muntoni","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008517","article-title":"Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies","author":"Jain","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.009_bib0019","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/acn3.51172","article-title":"LAMA2-related muscular dystrophy: natural history of a large pediatric cohort","volume":"7","author":"Zambon","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0020","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/epi.16493","article-title":"Epilepsy in LAMA2-related muscular dystrophy: an electro-clinico-radiological characterization","volume":"61","author":"Natera-de Benito","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.nmd.2021.07.009_bib0021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnmol.2020.00118","article-title":"Brain dysfunction in LAMA2-related congenital muscular dystrophy: lessons from human case reports and mouse models","volume":"13","author":"Arreguin","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.nmd.2021.07.009_bib0022","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jnnp-2013-307052","article-title":"Ullrich congenital muscular dystrophy: clinicopathological features, natural history and pathomechanism(s)","volume":"86","author":"Yonekawa","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.07.009_bib0023","doi-asserted-by":"crossref","first-page":"e1413","DOI":"10.1212\/WNL.0000000000011499","article-title":"Association of initial maximal motor ability with long-term functional outcome in patients with COL6-related dystrophies","volume":"96","author":"Natera-de Benito","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.009_bib0024","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cge.13886","article-title":"Genetic variations and clinical spectrum of dystroglycanopathy in a large cohort of Chinese patients","volume":"99","author":"Song","year":"2021","journal-title":"Clin Genet"},{"key":"10.1016\/j.nmd.2021.07.009_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mam.2016.07.003","article-title":"Mechanistic aspects of the formation of \u03b1-dystroglycan and therapeutic research for the treatment of \u03b1-dystroglycanopathy: a review","volume":"51","author":"Taniguchi-Ikeda","year":"2016","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.nmd.2021.07.009_bib0026","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.nmd.2016.12.010","article-title":"220th ENMC workshop: dystroglycan and the dystroglycanopathies naarden, the Netherlands, 27\u201329 May 2016","volume":"27","author":"Brown","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.009_bib0027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3174\/ajnr.A6858","article-title":"Characteristic cochlear hypoplasia in patients with walker-warburg syndrome: a radiologic study of the inner ear in \u03b1-dystroglycan-related muscular disorders","volume":"42","author":"Talenti","year":"2021","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0028","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.nmd.2018.08.001","article-title":"National registry of patients with fukuyama congenital muscular dystrophy in Japan","volume":"28","author":"Ishigaki","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.009_bib0029","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/acn3.51218","article-title":"Selenoprotein N-related myopathy: a retrospective natural history study to guide clinical trials","volume":"7","author":"Silwal","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0030","doi-asserted-by":"crossref","first-page":"e1512","DOI":"10.1212\/WNL.0000000000010327","article-title":"The clinical, histologic, and genotypic spectrum of SEPN1-related myopathy: a case series","volume":"95","author":"Villar-Quiles","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nmd.2021.07.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab075","article-title":"International retrospective natural history study of LMNA-related congenital muscular dystrophy","volume":"3","author":"Ben Yaou","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.nmd.2021.07.009_bib0032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13395-018-0163-0","article-title":"TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of \u03b1-dystroglycan and muscular dystrophy","volume":"8","author":"Larson","year":"2018","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.nmd.2021.07.009_bib0033","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/humu.23145","article-title":"Mutations in TRAPPC11 are associated with a congenital disorder of glycosylation","volume":"38","author":"Matalonga","year":"2017","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2021.07.009_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104184","article-title":"Compound heterozygous variants in GOSR2 associated with congenital muscular dystrophy: a case report","volume":"64","author":"Henige","year":"2021","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.nmd.2021.07.009_bib0035","first-page":"31","article-title":"A mutation in mannose-phosphate-dolichol utilization defect 1 reveals clinical symptoms of congenital disorders of glycosylation type I and dystroglycanopathy","volume":"50","author":"van Tol","year":"2019","journal-title":"JIMD Rep"},{"key":"10.1016\/j.nmd.2021.07.009_bib0036","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ajhg.2017.01.024","article-title":"Mutations in INPP5K, encoding a phosphoinositide 5-phosphatase, cause congenital muscular dystrophy with cataracts and mild cognitive impairment","volume":"100","author":"Wiessner","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2021.07.009_bib0037","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajhg.2017.01.019","article-title":"Mutations in INPP5K cause a form of congenital muscular dystrophy overlapping marinesco-sj\u00f6gren syndrome and dystroglycanopathy","volume":"100","author":"Osborn","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2021.07.009_bib0038","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00401-019-02059-z","article-title":"MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement","volume":"138","author":"Donkervoort","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0039","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ng.2851","article-title":"Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling","volume":"46","author":"Logan","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2021.07.009_bib0040","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.celrep.2019.09.063","article-title":"Dysregulation of mitochondrial Ca(2+) uptake and sarcolemma repair underlie muscle weakness and wasting in patients and mice lacking MICU1","volume":"29","author":"Debattisti","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.nmd.2021.07.009_bib0041","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nmd.2020.12.009","article-title":"Persistently elevated CK and lysosomal storage myopathy associated with mucolipin 1 defects","volume":"31","author":"Zambon","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.07.009_bib0042","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ana.25772","article-title":"GGPS1 mutations cause muscular dystrophy\/hearing loss\/ovarian insufficiency syndrome","volume":"88","author":"Foley","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0043","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nmd.2021.07.009_bib0044","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/hum.2016.171","article-title":"Future of rAAV gene therapy: platform for RNAi, gene editing, and beyond","volume":"28","author":"Valdmanis","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nmd.2021.07.009_bib0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fnmol.2019.00305","article-title":"Linker protein repair of LAMA2 dystrophic neuromuscular basement membranes","volume":"12","author":"Yurchenco","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.nmd.2021.07.009_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2020.00001","article-title":"Laminin and integrin in LAMA2-related congenital muscular dystrophy: from disease to therapeutics","volume":"13","author":"Barraza-Flores","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.nmd.2021.07.009_bib0047","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.matbio.2018.06.005","article-title":"Extracellular matrix-driven congenital muscular dystrophies","volume":"71-72","author":"Mohassel","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.nmd.2021.07.009_bib0048","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.omtm.2018.10.004","article-title":"Dose-dependent effects of FKRP gene-replacement therapy on functional rescue and longevity in dystrophic mice","volume":"11","author":"Vannoy","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nmd.2021.07.009_bib0049","first-page":"131","article-title":"GMPPA defects cause a neuromuscular disorder with \u03b1-dystroglycan hyperglycosylation","author":"Franzka","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2021.07.009_bib0050","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/hmg\/ddy032","article-title":"Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage","volume":"27","author":"Sudo","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2021.07.009_bib0051","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.celrep.2016.02.017","article-title":"Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy","volume":"14","author":"Kanagawa","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.nmd.2021.07.009_bib0052","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature10456","article-title":"Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy","volume":"478","author":"Taniguchi-Ikeda","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.nmd.2021.07.009_bib0053","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41418-020-0587-z","article-title":"Defective endoplasmic reticulum-mitochondria contacts and bioenergetics in SEPN1-related myopathy","volume":"28","author":"Filipe","year":"2021","journal-title":"Cell Death Differ"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:11:17Z","timestamp":1760775077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0960896621001917"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.07.009","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Congenital muscular dystrophies: What is new?","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}